書誌事項
- タイトル別名
-
- A Clinical Study of Squamous Cell Carcinoma of the Maxillary Sinus
- ジョウガクドウ ヘンペイ ジョウヒ ガン レイ ノ リンショウテキ ケントウ
この論文をさがす
説明
<p>We conducted this study to evaluate the outcomes of patients with squamous cell carcinoma of the maxillary sinus treated primarily in our department. The subjects included 17 cases of squamous cell carcinoma without distant metastasis out of the 29 cases of malignant maxillary sinus tumors treated at our hospital between January 2010 and March 2022. We examined the patient characteristics, the TNM classification of the tumors, the clinical stage and treatment adopted, the survival rate, using Kaplan-Meier analysis, the time to recurrence, and the results of histopathological evaluation after concurrent chemoradiotherapy with intra-arterial cisplatin (RADPLAT) or intravenous cisplatin (CCRT).</p><p>The median age of the patients, consisting of 14 male and 3 female patients, was 65 years; the median observation period in this study was one year 11 months. The T stage distribution of the tumors was as follows: T1, 1 case; T2, 2 cases; T3, 2 cases; T4a, 10; cases and T4b, 2 cases. The N stage distribution was as follows: N1, 2 cases: and N2b, 2 cases. Of the 12 cases with stage III or IVA, disease, 9 received RADPLAT. For all 17 cases, the 5-year overall survival rate was 74.6%, and the 5-year disease-specific survival rate was 81.5%. The disease-specific survival rates were 100% at 28 months for patients with stage I to III disease, 85.7% at 60 months for stage IVA disease, and 50% at 15 months for stage IVB disease. The 5-year disease-specific survival rate in cases with lymph node metastasis was 33.3%, and lymph node metastasis was identified as a significantly poor prognostic factor. Recurrence was observed in 2 stage IVA cases, and 2 stage IVB cases failed to be cured by RADPLAT or CCRT. Among the cases that underwent curative resection or sinonasal endoscopic biopsy after RADPLAT or CCRT, tumor cells were not detected in 86% of cases. A sinonasal endoscopic biopsy should be performed when residual tumor is suspected after concurrent chemoradiotherapy. Radical resection can be avoided if there is no pathologically evident residual tumor.</p>
収録刊行物
-
- 耳鼻咽喉科臨床 補冊
-
耳鼻咽喉科臨床 補冊 164 (0), 41-48, 2024
耳鼻咽喉科臨床学会
